Mirae Asset Global Investments Co. Ltd. Grows Holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Mirae Asset Global Investments Co. Ltd. raised its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 47.7% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,556 shares of the company’s stock after buying an additional 826 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Centessa Pharmaceuticals were worth $40,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its stake in shares of Centessa Pharmaceuticals by 103.1% during the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after purchasing an additional 1,509 shares in the last quarter. Quarry LP increased its stake in shares of Centessa Pharmaceuticals by 47.8% during the second quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after purchasing an additional 3,108 shares in the last quarter. Sandia Investment Management LP purchased a new stake in shares of Centessa Pharmaceuticals during the second quarter worth about $90,000. Fred Alger Management LLC purchased a new stake in shares of Centessa Pharmaceuticals during the second quarter worth about $99,000. Finally, EntryPoint Capital LLC purchased a new stake in shares of Centessa Pharmaceuticals during the first quarter worth about $109,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Insider Transactions at Centessa Pharmaceuticals

In other news, CEO Saurabh Saha sold 4,169 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $12.32, for a total value of $51,362.08. Following the transaction, the chief executive officer now directly owns 827,755 shares in the company, valued at approximately $10,197,941.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Saurabh Saha sold 4,169 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $12.32, for a total value of $51,362.08. Following the transaction, the chief executive officer now directly owns 827,755 shares in the company, valued at approximately $10,197,941.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Gregory M. Weinhoff sold 12,198 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $12.17, for a total transaction of $148,449.66. Following the completion of the transaction, the insider now owns 241,171 shares in the company, valued at approximately $2,935,051.07. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 325,031 shares of company stock worth $5,213,043. 11.59% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on CNTA. BMO Capital Markets boosted their target price on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research note on Monday, September 16th. Guggenheim boosted their price target on shares of Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. B. Riley assumed coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, September 19th. They set a “buy” rating and a $33.00 price target on the stock. Jefferies Financial Group boosted their price target on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Finally, Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $11.00 to $26.00 in a research report on Thursday, September 19th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $25.17.

Centessa Pharmaceuticals Stock Performance

NASDAQ:CNTA opened at $16.00 on Wednesday. The company has a debt-to-equity ratio of 0.27, a current ratio of 13.29 and a quick ratio of 13.29. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of -10.19 and a beta of 1.47. The company’s 50-day moving average is $15.38 and its two-hundred day moving average is $11.70. Centessa Pharmaceuticals plc has a 1-year low of $5.58 and a 1-year high of $17.59.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Tuesday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Analysts forecast that Centessa Pharmaceuticals plc will post -1.68 EPS for the current year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.